Cynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results

MT Newswires Live06-17

Cynata Therapeutics (ASX:CYP) decided to terminate a phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease after primary evaluation results failed to meet expectations, according to a Wednesday filing with the Australian bourse.

The results showed no significant differences between the active and control groups in the primary endpoint of overall response rate or in the trial's key secondary endpoints, per the filing.

The phase 1 results for CYP-001 were "very positive," but the latest outcome fell "well short of what we were hoping for," said Cynata CEO Kilian Kelly.

The company will remain under voluntary suspension from ASX trading pending the results of a phase 3 trial of CYP-004 in patients with knee osteoarthritis, which are expected to be released within the week.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644713380?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644713380","market":"hk","top_or_hot":-1,"title":"Cynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a> (ASX:CYP) decided to terminate a phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease after primary evaluation results failed to meet expectations, according to a Wednesday filing with the Australian bourse.</p><p>The results showed no significant differences between the active and control groups in the primary endpoint of overall response rate or in the trial's key secondary endpoints, per the filing.</p><p>The phase 1 results for CYP-001 were \"very positive,\" but the latest outcome fell \"well short of what we were hoping for,\" said Cynata CEO Kilian Kelly.</p><p>The company will remain under voluntary suspension from ASX trading pending the results of a phase 3 trial of CYP-004 in patients with knee osteoarthritis, which are expected to be released within the week.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCynata Therapeutics Terminates Acute Graft Versus Host Disease Trial After Disappointing Phase 2 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-17 14:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CYP.AU\">Cynata Therapeutics</a> (ASX:CYP) decided to terminate a phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease after primary evaluation results failed to meet expectations, according to a Wednesday filing with the Australian bourse.</p><p>The results showed no significant differences between the active and control groups in the primary endpoint of overall response rate or in the trial's key secondary endpoints, per the filing.</p><p>The phase 1 results for CYP-001 were \"very positive,\" but the latest outcome fell \"well short of what we were hoping for,\" said Cynata CEO Kilian Kelly.</p><p>The company will remain under voluntary suspension from ASX trading pending the results of a phase 3 trial of CYP-004 in patients with knee osteoarthritis, which are expected to be released within the week.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2644713380","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644713380","pubTimestamp":1781676270,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cynata Therapeutics  decided to terminate a phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease after primary evaluation results failed to meet expectations, according to a Wednesday filing with the Australian bourse.The results showed no significant differences between the active and control groups in the primary endpoint of overall response rate or in the trial's key secondary endpoints, per the filing.The phase 1 results for CYP-001 were \"very positive,\" but the latest outcome fell \"well short of what we were hoping for,\" said Cynata CEO Kilian Kelly.The company will remain under voluntary suspension from ASX trading pending the results of a phase 3 trial of CYP-004 in patients with knee osteoarthritis, which are expected to be released within the week.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK4007":"制药","CYP.AU":"CYNATA THERAPEUTICS LTD","BK7501":"新冠治疗股","LENZ":"Therapeutics","BK4539":"次新股","BK4588":"碎股","BK4181":"酒店及度假村房地产投资信托","BK4585":"ETF&股票定投概念","BK4218":"酒店及度假村房地产信托","BK4139":"生物科技","BK7067":"生物科技","HST":"美国豪斯特酒店"},"translate_title":"Cynata Therapeutics在2期结果令人失望后终止急性移植物抗宿主病试验","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HST":1.5,"LENZ":1.5,"CYP.AU":1},"content_text":"Cynata Therapeutics (ASX:CYP) decided to terminate a phase 2 clinical trial of CYP-001 in patients with high-risk acute graft versus host disease after primary evaluation results failed to meet expectations, according to a Wednesday filing with the Australian bourse.The results showed no significant differences between the active and control groups in the primary endpoint of overall response rate or in the trial's key secondary endpoints, per the filing.The phase 1 results for CYP-001 were \"very positive,\" but the latest outcome fell \"well short of what we were hoping for,\" said Cynata CEO Kilian Kelly.The company will remain under voluntary suspension from ASX trading pending the results of a phase 3 trial of CYP-004 in patients with knee osteoarthritis, which are expected to be released within the week.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644713380","isCrawlerRequest":true}